EpiCept holds key strategic partnerships with leading members of the pharmaceutical industry which both support and validate the Company’s development efforts. Future milestone payments associated with these agreements have the potential to reach over $125 million as well as substantial royalty payments.

Myriad Genetics, Inc.

EpiCept is a licensor to Myriad Genetics, Inc. for the exclusive worldwide right to develop and commercialize the MX90745 series of apoptosis inducers. Under the terms of the agreement, Myriad is responsible for all clinical development and commercialization of compounds from this series. Myriad has initiated clinical trials for Azixa™* (MPC-6827), for the treatment of brain cancer and other solid tumors. The agreement requires that Myriad make licensing, research and milestone payments to EpiCept, assuming the successful commercialization of a compound for the treatment of cancer, as well as pay a royalty on product sales. The Company is eligible to receive up to $27 million in milestone payments from Myriad for the development of Azixa.

Endo Pharmaceuticals Inc.

EpiCept has granted Endo the exclusive worldwide right to commercialize LidoPAIN® BP. The Company also granted Endo worldwide rights to use certain aspects of its patents for the development of certain other non-sterile, topical lidocaine patches, including Lidoderm®, Endo's non-sterile topical lidocaine-containing patch for the treatment of chronic lower back pain. The Company is eligible to receive up to $90 million in milestones from the development of LidoPAIN BP and Lidoderm for back pain as well as a double digit royalty on the sale of LidoPAIN BP.

DURECT Corporation

EpiCept granted DURECT Corporation the exclusive, worldwide rights to certain of EpiCept’s intellectual property for a transdermal patch containing bupivacaine for the treatment of back pain. This agreement aligns with EpiCept’s strategy to broaden the application of its patent estate in managing back pain beyond the use of lidocaine. Under the terms of the agreement, EpiCept received a $1 million upfront payment in December 2006 and is eligible to receive up to an additional $9.0 million in milestone payments as well as certain royalty payments on future product sales.

*Azixa™ is a trademark of Myriad Genetics, Inc.